<div id="readability-page-1"><p>In a report released today, Corinne Johnson from Goldman Sachs maintained a Buy rating on Roivant Sciences, with a price target of <span id="expert-recommendation-target">$33.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Johnson covers the Healthcare sector, focusing on stocks such as Roivant Sciences, Rhythm Pharmaceuticals, and Halozyme. According to TipRanks, Johnson has an average return of <span>7.5%</span> and a 54.07% success rate on recommended stocks. </p> <p>In addition to Goldman Sachs, Roivant Sciences also received a Buy from H.C. Wainwright’s Douglas Tsao in a report issued today. However, yesterday, TR | OpenAI – 4o reiterated a Hold rating on Roivant Sciences (NASDAQ: ROIV).</p></div>

ROIV

<p>Goldman Sachs analyst Corinne Johnson maintained a Buy rating on Roivant Sciences with a $33 price target. Johnson, who covers the Healthcare sector, has a 7.5% average return and a 54.07% success rate. H.C. Wainwright also issued a Buy rating, while TR | OpenAI reiterated a Hold rating on Roivant Sciences.</p>

Goldman Sachs Keeps Their Buy Rating on Roivant Sciences (ROIV)